Section Edited by Howard L. Kaufman, MD, FACS
This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.
Oncolytic adenovirus decreases the proportion of TIM-3 subset of tumor-infiltrating CD8 T cells with correlation to improved survival in patients with cancerIlkka Liikanen, Saru Basnet, Dafne C A Quixabeira, Kristian Taipale, Otto Hemminki, Minna Oksanen, Matti Kankainen, Juuso Juhila, Anna Kanerva, Timo Joensuu, Siri Tähtinen, Akseli Hemminki
22 February 2022
CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse modelRuikun Wang, Jingru Chen, Wei Wang, Zhuoqian Zhao, Haoran Wang, Shiyu Liu, Fan Li, Yajuan Wan, Jie Yin, Rui Wang, Yuanke Li, Cuizhu Zhang, Hongkai Zhang, Youjia Cao
27 January 2022
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8 T cell immunity to reject ‘cold’ tumorsMonika Semmrich, Jean-Baptiste Marchand, Laetitia Fend, Matilda Rehn, Christelle Remy, Petra Holmkvist, Nathalie Silvestre, Carolin Svensson, Patricia Kleinpeter, Jules Deforges, Fred Junghus, Kirstie L Cleary, Mimoza Bodén, Linda Mårtensson, Johann FoloppeSee the full list of authors
19 January 2022
Short-course neoadjuvant in situ vaccination for murine melanomaTaylor J Aiken, David Komjathy, Matthew Rodriguez, Ashley Stuckwisch, Arika Feils, Vladimir Subbotin, Jen Birstler, Stephen D Gillies, Alexander L Rakhmilevich, Amy K Erbe, Paul M Sondel
17 January 2022
Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma modelsMarilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, Francesca Barone, Paul P Tak, Ghazaleh Tabatabai, James A Lederer, E Antonio Chiocca, Sean Lawler
11 January 2022
Live attenuated bacterium limits cancer resistance to CAR-T therapy by remodeling the tumor microenvironmentFengguang Guo, Jugal K Das, Koichi S Kobayashi, Qing-Ming Qin, Thomas A Ficht, Robert C Alaniz, Jianxun Song, Paul De Figueiredo
5 January 2022
An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockadeShuguang Zuo, Min Wei, Tiancheng Xu, Lingkai Kong, Bohao He, Shiqun Wang, Shibing Wang, Junhua Wu, Jie Dong, Jiwu Wei
23 December 2021
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trialVictor Moreno, Maria-Pilar Barretina-Ginesta, Jesús García-Donas, Gordon C Jayson, Patricia Roxburgh, Raúl Márquez Vázquez, Agnieszka Michael, Antonio Antón-Torres, Richard Brown, David Krige, Brian Champion, Iain McNeish
10 December 2021
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacyMaite Alvarez, Carmen Molina, Carlos E De Andrea, Myriam Fernandez-Sendin, Maria Villalba, Jose Gonzalez-Gomariz, Maria Carmen Ochoa, Alvaro Teijeira, Javier Glez-Vaz, Fernando Aranda, Miguel F Sanmamed, Maria E Rodriguez-Ruiz, Xinyi Fan, Wen H Shen, Pedro BerraondoSee the full list of authors
25 November 2021
Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapyLuis Enrique Munoz, Lei Huang, Ramireddy Bommireddy, Richa Sharma, Lenore Monterroza, Rohini N. Guin, Sarah G. Samaranayake, Christopher D. Pack, Sampath Ramachandiran, Shaker J.C. Reddy, Mala Shanmugam, Periasamy Selvaraj
23 November 2021